What is ProKidney Corp. (PROK) stock price today?

ProKidney Corp. (PROK) currently trades at $1.82 per share. The stock has a market capitalization of $552.59M and a P/E ratio of —x.

Is PROK stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, ProKidney Corp. has a Smart Value Score of 27/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is 2.05.

What is ProKidney Corp.'s revenue and earnings?

ProKidney Corp. has trailing twelve-month (TTM) revenue of $893000.00 with profit margins of 0.00%. Earnings per share (EPS) is $-0.52.

Is ProKidney Corp. financially healthy?

ProKidney Corp.'s Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of 2.05 places it in the grey zone.

PROK

ProKidney Corp.

NASDAQ: PROK · HEALTHCARE · BIOTECHNOLOGY

$1.82

-0.55% today

Updated 2026-04-29

Market cap

$552.59M

P/E ratio

—

P/S ratio

618.80x

EPS (TTM)

$-0.52

Dividend yield

—

52W range

$1 – $6

Volume

0.8M

Market cap

$552.59M

P/E ratio

—

P/S ratio

618.80x

EPS (TTM)

$-0.52

Dividend yield

—

52W range

$1 – $6

Volume

0.8M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

6.3

Growth

8.0

Quality

2.5

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

2.1

Altman Z-Score

Grey zone

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$6.25

+243.41%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy4 Buy2 Hold0 Sell1 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 196.10% QoQ

+ Debt/equity -0.00x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-38.27M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$76000.00	$893000.00	$893000.00
Net income	$-108.03M	$-35.47M	$-61.19M	$-68.99M	$-19.23M
EPS	—	—	—	—	$-0.52
Free cash flow	$-78.94M	$-124.27M	$-155.86M	$-135.31M	$-38.27M
Profit margin	—	—	-80,507.89%	-7,725.20%	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-01	WEBER, DARIN J.	Buy	400,000	—
2026-03-01	GIROLAMO, TODD C	Buy	600,000	—
2026-03-01	CULLETON, BRUCE	Buy	3,000,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
PROK	$552.59M	27	6.3	2.5	5.0	8.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

ProKidney Corp. trades at $1.82. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 2.05, it sits in the grey zone. TTM revenue stands at $893000.00.

Frequently asked questions

What is ProKidney Corp.'s stock price?

ProKidney Corp. (PROK) trades at $1.82.

Is ProKidney Corp. overvalued?

Smart Value Score 27/100 (Grade F, Strong Sell).

What is the price target of ProKidney Corp. (PROK)?

The analyst target price is $6.25, representing +243.4% upside from the current price of $1.82.

What is ProKidney Corp.'s revenue?

TTM revenue is $893000.00.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

2.05 — grey zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

prokidney.com

Quick metrics

P/S ratio618.80x

ROE-43.20%

Beta1.86

50D MA$2.05

200D MA$2.42

Shares out0.14B

Float0.09B

Short ratio—

Avg volume0.8M

Performance

1 week-11.00%

1 month+16.25%

3 months-15.84%

YTD-16.96%

1 year—

3 years—

5 years—

Compare

PROK vs LLY →PROK vs JNJ →PROK vs ABBV →Stock screener →